Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Management of trials in the development of cancer chemotherapy

British Journal of Cancer volume 37, pages 434–447 (1978)Cite this article

Abstract

Potential anti-cancer agents have classically undergone clinical assessment in Phase I, II and III trials. This paper examines the role of these trials and pre-clinical studies in the light of improving cancer chemotherapy. Many patients must now be treated with standard therapy before investigational drugs can be ethically used. The introduction of combined modality trials will require a very prolonged follow-up to demonstrate improved survival and recognize late onset of chronic toxicity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Authors
  1. C J Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S K Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Williams, C., Carter, S. Management of trials in the development of cancer chemotherapy. Br J Cancer 37, 434–447 (1978). https://doi.org/10.1038/bjc.1978.64

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1978.64

This article is cited by

Search

Advanced search

Quick links